Navigation Links
NIH News Confirms Trend in Stem Cell 'Storage' Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
Date:3/26/2009

SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- David Koos, Chairman and CEO of San Diego-based Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) announced today that the important discovery reported on Wednesday, March 25 by researchers at the National Institutes of Health (NIH; www.nih.gov), which has implications for Leukemia treatment and artificially culturing blood cells, validates a new direction for stem cell "storage" facilities that meet rigid state and federal regulatory requirements. The researchers deciphered a key sequence of events governing whether the stem cells that produce red and white blood cells remain anchored to the bone marrow, or migrate into the circulatory system - an important discovery that will advance understanding of how blood cells and immune cells are generated.

"The findings of NIH researchers have implications for culturing infection-fighting immune cells outside the body, where they could be temporarily held in storage during chemotherapy and other treatments which suppress the immune system. This discovery confirms a new trend for commercial stem cell storage facilities for research and treatment of diseases, and their important role in public and private stem cell research efforts now and into the future," said Koos.

BMSN, an emerging research and development biotechnology company, opened its commercial cryogenic stem cell storage and processing facility in 2008 focusing on stem cells derived from cord blood and peripheral blood. BMSN's 15,000 sq. ft. cryogenic stem cell banking facility is highly secured and technologically advanced and is now fully operational.

"There are about 30 private cord blood storage facilities in the U.S. and more than 150 of these facilities located worldwide," stated Koos.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. The company also commercializes medical devices and monitoring systems for the growing worldwide stem cell research market.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Bio-Matrix Scientific Group Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
4. Barr Confirms Patent Challenge of Focalin(R) XR
5. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
6. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
7. Icahn Confirms Intention to Nominate Three Directors at Biogen
8. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
9. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Research Confirms Better Oil from New DuPont High Oleic Soybean Trait
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 20, 2017 , ... Cybrexa Therapeutics , a start-up ... role of chief scientific officer. In this role, Dr. Paralkar will lead the ... CEO, Per Hellsund. , “I was impressed with Cybrexa’s revolutionary technology and excellent ...
(Date:9/20/2017)... MD (PRWEB) , ... September 20, 2017 , ... ... digital pathology, and Huron Digital Pathology , a provider of whole slide ... 2017 Pathology Visions conference . The workshop, entitled “Successfully Deploying a Best-in-Class Strategy ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... focused on molecular manufacturing and other transformative technologies, announced the winners for the ... and the other for Theory in nanotechnology/molecular manufacturing. , Established in 1993 and ...
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this ... high-performance fume hood. Along with the advantages and disadvantages of ductless, filtered fume ... hoods in the laboratory. , Attendees will learn from an industry expert about ...
Breaking Biology Technology:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
Breaking Biology News(10 mins):